See more : Coats Group plc (COA.L) Income Statement Analysis – Financial Results
Complete financial analysis of iCAD, Inc. (ICAD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of iCAD, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- The Japan Wool Textile Co., Ltd. (JWTXF) Income Statement Analysis – Financial Results
- San Gold Corporation (SGRCF) Income Statement Analysis – Financial Results
- ComF5 International, Inc. (CMFV) Income Statement Analysis – Financial Results
- Ameriprise Financial, Inc. (AMP) Income Statement Analysis – Financial Results
- HP Adhesives Limited (HPAL.BO) Income Statement Analysis – Financial Results
iCAD, Inc. (ICAD)
About iCAD, Inc.
iCAD, Inc. provides image analysis, workflow solutions, and radiation therapy for the treatment of cancer in the United States. It operates through two segments, Cancer Detection and Cancer Therapy. The company offers PowerLook platform, which hosts the AI algorithm solutions and manages the communications between imaging acquisition systems, and image storage and review systems; SecondLook, a machine learning-based cancer detection algorithm that analyzes 2D full-field digital mammography images to identify and mark suspicious masses and calcifications; and automated density assessment solutions, which provides automated, consistent, and standardized density assessment. It also offers ProFound AI, a deep-learning algorithm designed to detect malignant soft-tissue densities and calcifications in digital breast tomosynthesis; ProFound AI Risk, a tool that provides breast cancer risk estimation based on a screening mammogram; and magnetic resonance imaging applications, a tool to detect breast and prostate cancer. In addition, the company offers VeraLook, a solution designed to support the detection of colonic polyps in conjunction with CT Colonography. Further, it provides Xoft Axxent electronic brachytherapy systems for the treatment of early stage breast, non-melanoma skin, and gynecological cancers to university research and community hospitals, cancer care clinics, veterinary facilities, and dermatology offices. The company sells its products through direct sales organizations, as well as through various original equipment manufacturer partners, distributors, technology platform partners, and resellers. It also exports its products in Europe, Taiwan, Canada, China, and internationally. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was incorporated in 1984 and is headquartered in Nashua, New Hampshire.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 17.32M | 27.94M | 33.64M | 29.70M | 31.34M | 25.62M | 28.10M | 26.34M | 41.55M | 43.92M | 33.07M | 28.28M | 28.65M | 24.58M | 28.11M | 37.49M | 26.61M | 19.72M | 19.77M | 23.31M | 6.52M | 5.00M | 4.84M | 7.79M | 6.70M | 5.30M | 7.90M | 11.30M | 20.60M | 24.40M | 20.60M | 23.00M | 11.90M | 21.70M | 18.40M | 11.20M | 2.70M |
| Cost of Revenue | 2.78M | 8.13M | 9.40M | 8.34M | 7.11M | 6.19M | 9.93M | 7.82M | 12.20M | 12.70M | 9.98M | 8.24M | 8.63M | 3.15M | 4.62M | 6.18M | 5.26M | 4.29M | 4.64M | 6.53M | 2.94M | 5.16M | 3.94M | 5.27M | 4.50M | 3.40M | 4.90M | 7.10M | 12.00M | 13.50M | 11.70M | 10.40M | 6.90M | 12.10M | 12.10M | 7.60M | 7.10M |
| Gross Profit | 14.54M | 19.81M | 24.24M | 21.35M | 24.23M | 19.43M | 18.18M | 18.52M | 29.35M | 31.23M | 23.09M | 20.03M | 20.03M | 21.43M | 23.49M | 31.32M | 21.36M | 15.43M | 15.13M | 16.78M | 3.58M | -161.46K | 898.89K | 2.52M | 2.20M | 1.90M | 3.00M | 4.20M | 8.60M | 10.90M | 8.90M | 12.60M | 5.00M | 9.60M | 6.30M | 3.60M | -4.40M |
| Gross Profit Ratio | 83.94% | 70.90% | 72.07% | 71.90% | 77.30% | 75.84% | 64.68% | 70.31% | 70.63% | 71.09% | 69.81% | 70.84% | 69.90% | 87.20% | 83.56% | 83.53% | 80.25% | 78.24% | 76.55% | 71.97% | 54.88% | -3.23% | 18.59% | 32.38% | 32.84% | 35.85% | 37.97% | 37.17% | 41.75% | 44.67% | 43.20% | 54.78% | 42.02% | 44.24% | 34.24% | 32.14% | -162.96% |
| Research & Development | 5.16M | 8.59M | 9.19M | 8.11M | 9.27M | 9.45M | 9.33M | 9.52M | 9.16M | 8.16M | 7.69M | 7.77M | 10.79M | 6.60M | 7.22M | 7.12M | 4.50M | 5.26M | 4.79M | 4.83M | 2.38M | 1.63M | 751.47K | 709.60K | 800.00K | 1.10M | 1.40M | 2.40M | 2.80M | 2.90M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 9.32M | 11.23M | 10.41M | 9.12M | 7.44M | 9.12M | 7.88M | 7.68M | 8.79M | 8.04M | 6.74M | 6.97M | 10.08M | 9.92M | 7.35M | 19.43M | 17.96M | 16.61M | 15.10M | 12.21M | 9.28M | 7.58M | 2.69M | 2.89M | 3.00M | 3.00M | 3.40M | 5.00M | 6.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 7.74M | 13.69M | 15.14M | 13.31M | 13.63M | 8.69M | 10.50M | 10.18M | 12.40M | 12.47M | 10.43M | 10.71M | 13.68M | 11.49M | 11.04M | 11.96M | 10.78M | 9.23M | 8.15M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 17.06M | 24.93M | 25.54M | 22.43M | 21.08M | 17.81M | 18.38M | 17.85M | 21.19M | 20.51M | 17.17M | 17.67M | 23.76M | 21.40M | 18.39M | 19.43M | 17.96M | 16.61M | 15.10M | 12.21M | 9.28M | 7.58M | 2.69M | 2.89M | 3.00M | 3.00M | 3.40M | 5.00M | 6.00M | 5.10M | 8.00M | 7.20M | 8.80M | 9.80M | 7.70M | 7.90M | 0.00 |
| Other Expenses | 0.00 | 224.00K | 240.00K | 199.00K | 276.00K | 110.00K | 18.00K | 10.00K | 21.00K | 37.00K | 19.00K | 35.00K | -4.16M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 623.70K | 600.00K | 700.00K | 1.30M | 2.20M | 2.00M | 1.60M | 1.30M | 1.20M | 700.00K | 2.00M | 1.80M | 600.00K | 500.00K |
| Operating Expenses | 22.23M | 33.74M | 34.98M | 30.74M | 30.62M | 27.56M | 28.16M | 28.49M | 31.99M | 30.41M | 24.86M | 25.44M | 30.39M | 28.00M | 25.61M | 26.55M | 22.46M | 21.87M | 19.89M | 17.04M | 11.66M | 9.21M | 3.44M | 4.22M | 4.40M | 4.80M | 6.10M | 9.60M | 10.80M | 9.60M | 9.30M | 8.40M | 9.50M | 11.80M | 9.50M | 8.50M | 500.00K |
| Cost & Expenses | 25.01M | 41.87M | 44.37M | 39.09M | 37.74M | 33.75M | 38.09M | 36.31M | 44.19M | 43.11M | 34.84M | 33.69M | 39.02M | 31.15M | 30.23M | 32.73M | 27.72M | 26.16M | 24.52M | 23.58M | 14.60M | 14.37M | 7.38M | 9.49M | 8.90M | 8.20M | 11.00M | 16.70M | 22.80M | 23.10M | 21.00M | 18.80M | 16.40M | 23.90M | 21.60M | 16.10M | 7.60M |
| Interest Income | 729.00K | 213.00K | 15.00K | 97.00K | 344.00K | 110.00K | 18.00K | 10.00K | 21.00K | 37.00K | 19.00K | 35.00K | 24.00K | 73.27K | 119.10K | 106.03K | 74.15K | 102.96K | 127.53K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 16.00K | 10.00K | 141.00K | 476.00K | 784.00K | 504.00K | 124.00K | 63.00K | 650.00K | 2.64M | 3.28M | 3.42M | 419.00K | 269.00 | 9.33K | 280.63K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 409.00K | 521.00K | 557.00K | 578.00K | 673.00K | 708.00K | 1.49M | 2.31M | 3.35M | 3.53M | 2.43M | 2.80M | 3.17M | 1.64M | 1.92M | 1.84M | 1.70M | 1.66M | 1.63M | 1.34M | 667.89K | 389.88K | 486.14K | 623.70K | 600.00K | 700.00K | 1.30M | 2.20M | 2.00M | 1.60M | 1.30M | 1.20M | 700.00K | 2.00M | 1.80M | 600.00K | 500.00K |
| EBITDA | -6.57M | -9.50M | -10.55M | -16.52M | -12.05M | -7.31M | -12.66M | -7.67M | -28.43M | 4.34M | -1.77M | -3.12M | -34.42M | -4.58M | -80.66K | 6.71M | 598.07K | -4.67M | -3.00M | 1.07M | -7.42M | -8.98M | -2.05M | -1.07M | -1.60M | -2.20M | -1.80M | -3.20M | -200.00K | 2.90M | 900.00K | 5.40M | -3.80M | -200.00K | -1.40M | -4.30M | -4.40M |
| EBITDA Ratio | -37.91% | -47.38% | -30.20% | -54.48% | -38.45% | -30.30% | -30.16% | -29.06% | 1.76% | 9.97% | 2.04% | -9.13% | -25.02% | -19.76% | -7.55% | 17.62% | 2.25% | -24.21% | -15.79% | 4.60% | -113.73% | -179.60% | -42.49% | -13.75% | -23.88% | -41.51% | -55.70% | -28.32% | 12.14% | 11.89% | 4.37% | 23.48% | -31.93% | -0.92% | -7.61% | -38.39% | -44.44% |
| Operating Income | -7.69M | -13.93M | -10.73M | -9.39M | -6.40M | -8.13M | -14.17M | -9.97M | -30.08M | 815.00K | -1.78M | -5.41M | -37.19M | -6.57M | -2.12M | 4.77M | -1.10M | -6.44M | -4.75M | -267.22K | -8.08M | -9.37M | -2.54M | -1.70M | -2.20M | -2.90M | -3.10M | -5.40M | -2.20M | 1.30M | -400.00K | 4.20M | -4.50M | -2.20M | -3.20M | -4.90M | -4.90M |
| Operating Income Ratio | -44.40% | -49.85% | -31.90% | -31.61% | -20.41% | -31.73% | -50.42% | -37.85% | -72.39% | 1.86% | -5.37% | -19.14% | -129.81% | -26.74% | -7.55% | 12.71% | -4.15% | -32.65% | -24.05% | -1.15% | -123.98% | -187.40% | -52.54% | -21.76% | -32.84% | -54.72% | -39.24% | -47.79% | -10.68% | 5.33% | -1.94% | 18.26% | -37.82% | -10.14% | -17.39% | -43.75% | -181.48% |
| Total Other Income/Expenses | 699.00K | 164.00K | -512.00K | -8.18M | -7.11M | -845.00K | -106.00K | -53.00K | -2.35M | -1.67M | -5.71M | -3.92M | -395.00K | 348.27K | 109.77K | -174.60K | -434.73K | -199.28K | -3.96K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.60M | 0.00 | -2.70M | -300.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -3.20M |
| Income Before Tax | -6.99M | -13.77M | -11.24M | -17.57M | -13.51M | -8.98M | -14.27M | -10.02M | -32.43M | -856.00K | -7.48M | -9.33M | -37.59M | -6.22M | -2.01M | 4.59M | -1.54M | -6.64M | -4.76M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -500.00K | 0.00 | -4.90M | 1.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -8.10M |
| Income Before Tax Ratio | -40.36% | -49.28% | -33.43% | -59.17% | -43.10% | -35.03% | -50.79% | -38.06% | -78.05% | -1.95% | -22.63% | -33.00% | -131.18% | -25.33% | -7.15% | 12.25% | -5.78% | -33.66% | -24.07% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -6.33% | 0.00% | -23.79% | 4.10% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -300.00% |
| Income Tax Expense | 20.00K | -116.00K | 1.00K | 38.00K | 43.00K | 42.00K | -18.00K | 76.00K | 16.00K | 153.00K | 126.00K | 43.00K | 419.00K | 0.00 | -43.57K | 235.00K | 0.00 | 0.00 | 0.00 | 561.04K | 114.66K | 48.17K | 80.11K | 132.01K | 1.80M | 500.00K | -2.30M | 700.00K | 3.10M | 100.00K | 400.00K | 400.00K | 500.00K | 100.00K | 300.00K | 400.00K | 3.70M |
| Net Income | -4.85M | -13.66M | -11.25M | -17.61M | -13.55M | -9.02M | -14.26M | -10.10M | -32.45M | -1.01M | -7.61M | -9.37M | -37.59M | -6.22M | -1.97M | 4.36M | -1.54M | -6.64M | -4.76M | -828.26K | -8.20M | -9.42M | -2.62M | -1.83M | -4.00M | -3.40M | -800.00K | -6.10M | -5.30M | 900.00K | -800.00K | 3.80M | -5.00M | -2.30M | -3.50M | -5.30M | -8.60M |
| Net Income Ratio | -27.99% | -48.87% | -33.43% | -59.30% | -43.24% | -35.19% | -50.73% | -38.34% | -78.08% | -2.30% | -23.01% | -33.15% | -131.18% | -25.33% | -7.00% | 11.62% | -5.78% | -33.66% | -24.07% | -3.55% | -125.74% | -188.36% | -54.20% | -23.45% | -59.70% | -64.15% | -10.13% | -53.98% | -25.73% | 3.69% | -3.88% | 16.52% | -42.02% | -10.60% | -19.02% | -47.32% | -318.52% |
| EPS | -0.27 | -0.54 | -0.45 | -0.80 | -0.74 | -0.54 | -0.87 | -0.63 | -2.07 | -0.07 | -0.70 | -0.87 | -3.45 | -0.68 | -0.22 | 0.50 | -0.20 | -0.90 | -0.65 | -0.12 | -1.52 | -2.25 | -0.94 | -0.68 | -1.58 | -1.68 | -0.44 | -3.80 | -3.34 | 0.55 | -0.50 | 2.45 | -3.35 | -1.55 | -2.50 | -4.40 | -8.20 |
| EPS Diluted | -0.27 | -0.54 | -0.45 | -0.80 | -0.74 | -0.54 | -0.87 | -0.63 | -2.07 | -0.07 | -0.70 | -0.87 | -3.45 | -0.68 | -0.22 | 0.50 | -0.20 | -0.90 | -0.65 | -0.12 | -1.52 | -2.25 | -0.94 | -0.68 | -1.58 | -1.68 | -0.40 | -3.80 | -3.34 | 0.55 | -0.50 | 2.45 | -3.35 | -1.55 | -2.50 | -4.40 | -8.20 |
| Weighted Avg Shares Out | 25.61M | 25.20M | 24.78M | 22.14M | 18.38M | 16.68M | 16.34M | 15.93M | 15.67M | 14.10M | 10.84M | 10.77M | 10.91M | 9.17M | 9.10M | 8.34M | 7.67M | 7.38M | 7.33M | 6.81M | 5.39M | 4.19M | 2.79M | 2.67M | 2.53M | 2.03M | 1.81M | 1.61M | 1.59M | 1.64M | 1.60M | 1.55M | 1.49M | 1.48M | 1.40M | 1.20M | 1.05M |
| Weighted Avg Shares Out (Dil) | 25.61M | 25.20M | 24.78M | 22.14M | 18.38M | 16.69M | 16.34M | 15.93M | 15.69M | 14.10M | 10.84M | 10.80M | 10.91M | 9.17M | 9.10M | 8.55M | 7.67M | 7.38M | 7.33M | 6.81M | 5.39M | 4.19M | 2.79M | 2.67M | 2.53M | 2.03M | 2.00M | 1.61M | 1.59M | 1.64M | 1.60M | 1.55M | 1.49M | 1.48M | 1.40M | 1.20M | 1.05M |
Icad (ICAD) Reports Q2 Loss, Lags Revenue Estimates
Icad (ICAD) delivered earnings and revenue surprises of 0% and 15.08%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
iCAD Reports Financial Results For Second Quarter 2022
Company reports accelerating demand for subscription and cloud-based business models driving long-term recurring revenue opportunities
iCAD Presents its Complete Suite of Breast Cancer AI Solutions at the European Congress of Radiology
Compelling clinical evidence shows ProFound AI Risk accurately identified a high-risk group of women with 32 times higher risk of breast cancer than the general population Compelling clinical evidence shows ProFound AI Risk accurately identified a high-risk group of women...
ProFound AI Risk Real-World Case Studies to be featured in iCAD's “ProFound Insights, ProFound Impact” Webinar Series
Leading radiologists to highlight clinical examples demonstrating power of iCAD's complete suite of ProFound AI Breast Health Solutions Leading radiologists to highlight clinical examples demonstrating power of iCAD's complete suite of ProFound AI Breast Health Solutions
Global Medical Electronics Market (2022 to 2027) - Advances in Sensors and Digital Technologies Presents Opportunities - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Global Medical Electronics Market (2022-2027) by Component, End-User Product, Medical Procedure, Medical Device Classification, Application, Geography, Competitive Analysis and the Impact of Covid-19 with Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering. The Global Medical Electronics Market...
Global Cancer Diagnostics Partnering Deal Terms and Agreements Analysis Report/Directory 2015-2022 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Global Cancer Diagnostics Partnering Terms and Agreements 2015-2022" report has been added to ResearchAndMarkets.com's offering. The Global Cancer Diagnostics Partnering Terms and Agreements 2015-2022 report provides comprehensive access to available deals and contract documents for over 1000 Cancer...
iCAD to Present at the JMP Securities Life Sciences Conference on June 15-16, 2022
NASHUA, N.H., June 06, 2022 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the Company will participate in the JMP Securities Life Sciences Conference, taking place June...
5 Growth Stocks to Buy Now
EPS estimates are generally a strong indication of future growth. That's just one part of finding reliable growth stocks.
iCAD Announces CFO Transition
Stephen P. Sarno appointed as interim Chief Financial Officer to the Company, effective immediately Stephen P. Sarno appointed as interim Chief Financial Officer to the Company, effective immediately
New Research Finds iCAD's ProFound AI Risk for Digital Breast Tomosynthesis is 2.4x More Accurate than Traditional Lifetime Risk Models
Using U.S. guidelines, ProFound AI Risk found 14% of women studied who had a negative screen had almost 20 times higher risk of developing breast cancer in the next year than the general risk population Using U.S. guidelines, ProFound AI...
Source: https://incomestatements.info
Category: Stock Reports